Kestra Investment Management LLC Purchases Shares of 341 Prestige Consumer Healthcare Inc. (NYSE:PBH)

Kestra Investment Management LLC acquired a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 341 shares of the company’s stock, valued at approximately $27,000.

Several other large investors have also modified their holdings of PBH. Truist Financial Corp acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $345,000. Sanctuary Advisors LLC boosted its stake in Prestige Consumer Healthcare by 5.4% during the 4th quarter. Sanctuary Advisors LLC now owns 18,175 shares of the company’s stock valued at $1,425,000 after purchasing an additional 927 shares during the period. Principal Financial Group Inc. grew its holdings in Prestige Consumer Healthcare by 3.2% in the 4th quarter. Principal Financial Group Inc. now owns 256,526 shares of the company’s stock valued at $20,032,000 after buying an additional 7,890 shares during the last quarter. Congress Asset Management Co. increased its position in Prestige Consumer Healthcare by 5.0% in the 4th quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock worth $70,964,000 after buying an additional 43,619 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Prestige Consumer Healthcare by 3.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock worth $126,274,000 after buying an additional 49,331 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PBH. DA Davidson raised their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Canaccord Genuity Group boosted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday, January 24th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average price target of $92.60.

Prestige Consumer Healthcare Trading Down 0.1 %

Shares of PBH opened at $84.66 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.19 billion, a PE ratio of 19.83, a PEG ratio of 2.69 and a beta of 0.50. Prestige Consumer Healthcare Inc. has a 1 year low of $62.35 and a 1 year high of $88.36. The stock has a 50 day simple moving average of $79.47 and a 200-day simple moving average of $76.56.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.